GRAIL, Inc. (BMV:GRAL)
Mexico · Delayed Price · Currency is MXN | Market Cap | 58.00B +166.7% |
| Revenue (ttm) | 2.89B +23.1% |
| Net Income | -6.84B |
| EPS | -170.34 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20 |
| Open | 1,325.00 |
| Previous Close | n/a |
| Day's Range | 1,325.00 - 1,325.00 |
| 52-Week Range | 635.65 - 1,828.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About GRAIL
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology... [Read more]
Financial Performance
In 2025, GRAIL's revenue was $147.17 million, an increase of 17.18% compared to the previous year's $125.60 million. Losses were -$408.35 million, -79.85% less than in 2024.
Financial numbers in USD Financial StatementsNews
GRAIL Transcript: Canaccord Genuity's 46th Annual Growth Conference
Strong first-half growth was driven by digital health and employer channels, with expanded sales force and streamlined physician integrations. Key clinical studies showed significant reductions in late-stage cancer detection, and an FDA AdCom is set for September. $900 million in cash supports ongoing expansion and regulatory milestones.
US FDA to hold advisory meeting to review Grail's multi-cancer test
Grail said on Friday the U.S. FDA plans to hold a meeting of outside experts to review its multi-cancer screening test Galleri in September, sending its shares up 4% in morning trade.
Grail announces FDA advisory committee meeting to review Galleri test PMA
GRAIL (GRAL) announced that the U.S. Food and Drug Administration’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept. 23 to review…
GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
MENLO PARK, Calif., Aug. 7, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the U.S. Food and D...
GRAIL Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue and test volume growth, driven by Galleri's robust clinical validation and expanded commercial efforts. The company completed a $110M investment from Samsung, advanced toward FDA approval, and continued international expansion, while maintaining a strong cash position.
GRAIL Earnings release: Q2 2026
GRAIL released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
GRAIL Quarterly report: Q2 2026
GRAIL has published its Q2 2026 quarterly earnings report on August 5, 2026.
Grail reports Q2 EPS ($2.56), consensus ($2.43)
Reports Q2 revenue $44.7M, consensus $42.4M. “GRAIL (GRAL) continues to execute across our clinical and commercial priorities. We presented detailed performance, safety, and clinical utility results f...
GRAIL Reports Second Quarter 2026 Financial Results
Q2 Galleri ® Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew 24% to $42.6 Million Galleri Test Volume and Revenue are up 42% and 30% Year-Over-Year, Respectively...
GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference
MENLO PARK, Calif., July 30, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 4, 2026 in Grail, Inc. Lawsuit - GRAL
Wall Street's Reassessment of Grail: How Analyst Expectations Built on Positive NHS-Galleri Representations Collapsed Alongside GRAL's $51.32 Per-Share Decline NEW YORK, July 30, 2026 /PRNewswire/ -- ...
GRAIL to Announce Second Quarter 2026 Financial Results
MENLO PARK, Calif., July 29, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue fina...
$GRAL Fraud Notification: GRAIL, Inc. Sued for Fraud Over Misrepresentations about its Trial Results – Investors Notified to Contact BFA Law
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) and certain o...
Grail’s Gallery cancer detection test adopted by Priority Health
Grail (GRAL) announced a collaboration with Priority Health, a nonprofit health plan and the third largest provider-sponsored health plan in the nation, to make Grail’s Galleri multi-cancer early dete...
Priority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri® Multi-Cancer Early Detection Blood Test to Employer Plans
MENLO PARK, Calif., July 16, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Pr...
Grail price target raised to $88 from $69 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Grail (GRAL) to $88 from $69 and keeps a Buy rating on the shares. The firm adjusted targets in…
Grail price target raised to $65 from $58 at Mizuho
Mizuho raised the firm’s price target on Grail (GRAL) to $65 from $58 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical device and…
$GRAL Fraud Notification: GRAIL, Inc. Sued for Securities Fraud After Trial Results Spark a 50% Stock Drop – Investors Notified to Contact BFA Law by August 4
A securities fraud class action lawsuit has been filed on behalf of GRAIL investors after its stock plummeted 50% because GRAIL allegedly misled investors relating to GRAIL's NHS-Galleri cancer trial,...
GRAIL, Inc. (GRAL) Securities Fraud: Contact Berger Montague to Discuss Your Rights
Philadelphia, Pennsylvania--(Newsfile Corp. - July 2, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) ("GRAIL" or the "Comp...
GRAL Investors Have Rights – If You Lost Money Investing in Grail, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Grail, Inc. (NASDAQ: GRAL) se...
GRAIL Completes $110 Million Equity Financing With Samsung Entities
MENLO PARK, Calif., June 25, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the closing of its prev...
GRAIL Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and governance procedures. Both proposals passed, with final results to be filed with the SEC. No shareholder questions were addressed during the session.
GRAL Breaking News: GRAIL, Inc. Sued for Securities Fraud after Trial Results Lead to 50% Stock Drop – Investors Notified to Contact BFA Law
NEW YORK--(BUSINESS WIRE)---- $GRAL #BFA--GRAIL, Inc. Sued for Securities Fraud after Trial Results Lead to 50% Stock Drop – Investors Notified to Contact BFA Law.
GRAIL, INC. (GRAL) INVESTOR ALERT Investors With Large Losses in GRAIL, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, June 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
GRAIL Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Significant reductions in late-stage cancer and emergency presentations were demonstrated in a large RCT, supporting clinical utility and future coverage. FDA approval and international expansion are key priorities, with strong self-pay and digital health growth driving near-term volumes.